首页> 外文OA文献 >The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors
【2h】

The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors

机译:临床研究报告的使用提升了系统评价的质量:系统审查作者调查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background Clinical study reports (CSRs) are produced for marketing authorisation applications. They often contain considerably more information about, and data from, clinical trials than corresponding journal publications. Use of data from CSRs might help circumvent reporting bias, but many researchers appear to be unaware of their existence or potential value. Our survey aimed to gain insight into the level of familiarity, understanding and use of CSRs, and to raise awareness of their potential within the systematic review community. We also aimed to explore the potential barriers faced when obtaining and using CSRs in systematic reviews. Methods Online survey of systematic reviewers who (i) had requested or used CSRs, (ii) had considered but not used CSRs and (iii) had not considered using CSRs was conducted. Cochrane reviewers were contacted twice via the Cochrane monthly digest. Non-Cochrane reviewers were reached via journal and other website postings. Results One hundred sixty respondents answered an open invitation and completed the questionnaire; 20/160 (13%) had previously requested or used CSRs and other regulatory documents, 7/160 (4%) had considered but not used CSRs and 133/160 (83%) had never considered this data source. Survey respondents mainly sought data from the European Medicines Agency (EMA) and/or the Food and Drug Administration (FDA). Motivation for using CSRs stemmed mainly from concerns about reporting bias 11/20 (55%), specifically outcome reporting bias 11/20 (55%) and publication bias 5/20 (25%). The barriers to using CSRs noted by all types of respondents included current limited access to these documents (43 respondents), the time and resources needed to obtain and include these data in evidence syntheses (n = 25) and lack of guidance about how to use these sources in systematic reviews (n = 26). Conclusions Most respondents (irrespective of whether they had previously used them) agreed that access to CSRs is important, and suggest that further guidance on how to use and include these data would help to promote their use in future systematic reviews. Most respondents who received CSRs considered them to be valuable in their systematic review and/or meta-analysis.
机译:摘要背景研究报告(CSRS)是用于营销授权应用。它们通常包含关于相应的临床试验的更多信息和数据,而不是相应的期刊出版物。来自CSRS的数据可能有助于规避报告偏见,但许多研究人员似乎不知道其存在或潜在价值。我们的调查旨在深入了解CSR的熟悉程度,理解和使用水平,并提高对系统审查界内潜力的认识。我们还旨在探讨在系统评价中获得和使用CSR时面临的潜在障碍。方法对(i)所要求或使用CSRS的系统审阅者的在线调查已考虑但未使用CSRS和(iii)进行了使用CSRS。 Cochrane评论者通过Cochrane每月消化联系两次。通过期刊和其他网站帖子达成了非Cochrane评论者。结果一百六十次受访者回答了公开邀请,并完成了调查问卷; 20/160(13%)先前要求或使用CSRS和其他监管文件,7/160(4%)已考虑但未使用CSRS,133/160(83%)从未考虑过此数据源。调查受访者主要寻求欧洲药物局(EMA)和/或食品和药物管理局(FDA)的数据。使用CSRS的动机主要来自关于报告偏见11/20(55%)的担忧,特别是结果报告偏见11/20(55%)和出版物偏见5/20(25%)。所有类型受访者指出的使用CSRS的障碍包括对这些文件的当前有限的访问(43名受访者),获得并包括在证据合成中所需的时间和资源(n = 25),并且缺乏关于如何使用的指导这些来源在系统性评论中(n = 26)。结论大多数受访者(无论他们以前使用它们)是否同意对CSR的访问很重要,并建议有关如何使用的进一步指导,并包括这些数据将有助于促进其在未来的系统评论中的使用。收到CSR的大多数受访者认为他们在系统审查和/或荟萃分析中是有价值的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号